ClinicalTrials.gg
CompletedNCT04185558Updated May 14, 2024

Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

An interventional study of ActiGraft and Standard of Care in Diabetic Foot and Chronic Ulcer, sponsored by RedDress Ltd.. Completed at 16 sites in 3 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by RedDress Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
102nd of 322
119 · median 60
Started
2019
with 21 others
No phase
186 of 381
38 open now
Registered
222nd of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 102nd largest by enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2019, is one of 186 with no phase, and was the 222nd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

  • The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers.
  • The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone.
  • The target ulcers are evaluated weekly by the investigator. The subject is treated once a week, to receive weekly applications of the ActiGraft + SOC or SOC until for up to 12 weeks or until the study ulcer has completely healed (i.e., 100% closure as assessed by the Investigator and blinded assessor and confirmed 2 weeks later at the healing confirmation visit (HCV). One additional visit per week is optional for both arms, for the purpose of changing only (1) the secondary dressing in the ActiGraft arm or (2) change the standard of care dressing in the control arm.
  • Immediately after the study ulcer is confirmed as completely healed, subjects will enter the 12-week Follow-up Phase. During the Follow-Up phase, subjects will be evaluated twice during the first month and then monthly for two additional visits every 4 weeks until the completion of the 12-week Follow-up Phase.
03

Conditions studied

  • Diabetic Foot
  • Chronic Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥19 years of age and has type 1 or 2 diabetes
  • Chronic neuropathic DFU, located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts (Minor tunneling and undermining will be included).
  • Ulcer size between 1 cm2 and 28 cm2 (post-debridement).
  • For subjects with potentially multiple eligible DFUs, the largest non-healing wound will be selected.
  • Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the first day of screening (i.e., day -14). Subjects will need to meet all inclusion criteria, including lack of ulcer healing until randomization day.
  • Study ulcer separated from other ulcers by at least 1 cm.
  • Ulcer or affected limb free of clinical signs of infection.
  • Post-debridement, ulcer free of necrotic tissue.
  • Adequate circulation to the affected extremity as demonstrated by at least one of the following: (1) Transcutaneous oxygen test (TcPO2) ≥ 30 mm Hg,; (2) Ankle Brachial Index (ABI) between 0.7 and 1.2; (3)Triphasic or biphasic Doppler arterial waveforms at the ankle of affected leg; (4) Toe Brachial Index > 0.6
  • ≤ 12.0%
  • Demonstrated adequate offloading regimen.
  • Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft.
  • Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of in order to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure ulcers.).
  • Known or suspected ulcer of the index ulcer.
  • Active Charcot of the affected foot
  • Presence of underlying osteomyelitis.
  • Subject with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection.
  • History of alcohol or substance abuse, within the previous 2 months
  • Subject has participated in another clinical trial involving a device or a systemically administered study drug or treatment within 30 days of randomization visit.
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic (more than 10mg per day), therapy, disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the foot, planned vascular surgery on the study ulcer limb on the 90 days from screening, angioplasty or thrombolysis, chemotherapy).
  • Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled to receive during the study.
  • Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.
  • Wound on a subject who has a of less than 12 months.
  • Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the form.
  • Cannot withdraw blood in the required amount (up to 15 mL per week) technically.
  • Known coagulation problems, abnormal level or if heparin is given intravenously. Subjects who are taking coumadin, aspirin, Plavix (clopidogrel), Eliquis or Pradaxa will not be excluded.
  • anemia (\< 9 g/dL).
  • Subject has a history of or any of the following intercurrent illnesses or conditions that would compromise the safety of the subject, or the normal wound healing process: (1) End stage renal disease; (2)Immunosuppression; (3) Severe malnutrition; (4) Liver disease; (5) Scleroderma; (6) Acquired immune deficiency disease (AIDS) or positive; (7) Active connective tissue disorder; (8)Exacerbation of sickle cell anemia
  • If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and standard of care phase, subject will be excluded.
  • Women who are pregnant or currently breast feeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    ActiGraft

    Whole blood clot (WBC) gel

    Device: ActiGraft

  • Active comparator
    Standard of Care

    Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap

    Device: Standard of Care

Interventions

  • DeviceActiGraft

    Whole Blood Clot (WBC) gel

  • DeviceStandard of Care

    Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap

06

What researchers measure

Primary outcomes

  1. Incidence of complete wound closure by 12 weeks

    Incidence of complete wound closure by 12 weeks using chi square (two-sided; alpha set at .05 level of significance), or Fischer exact test if one group has ≤ 5 completely closed wounds. Analysis will be adjusted using generalized linear modeling (logit function).

    Time frame: 12 weeks

Secondary outcomes

  1. Time to complete wound closure

    Time to complete wound closure using Cox regression

    Time frame: 12 weeks

  2. Percent area reduction (PAR)

    Percent area reduction (PAR) at 4 and 8 weeks.

    Time frame: 4 weeks and 8 weeks

  3. Nature, frequency, and severity of adverse events in the intent to treat population

    Nature, frequency, and severity (by CTCAE5) of adverse events

    Time frame: 12 weeks

  4. Number of patients showing a consistence wound closure post healing determination

    Time frame: 24 weeks

07

Study locations

16 sites
  • Institute for Advanced Wound Care
    Montgomery, Alabama 36111, United States
  • New Hope Podiatry Group Inc
    Los Angeles, California 90063, United States
  • Greater Los Angeles VA
    Los Angeles, California 90073, United States
  • Center for Clinical Research Inc
    San Francisco, California 94117, United States
  • Olive View UCLA Education & Research Institute
    Sylmar, California 91342, United States
  • Eric J Lullove DPM PA
    Coconut Creek, Florida 33073, United States
  • Future Health Research Clinic
    Miami, Florida 33175, United States
  • Barry University Clinical Research
    North Miami Beach, Florida 33169, United States
  • Pacific Vascular Institute
    Hilo, Hawaii 96720, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Wahab Consulting and Research LLC
    Las Vegas, Nevada 89148, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Wound Care South Africa
    Germiston, 0000, South Africa
  • Haute Care
    Lyttelton, South Africa
  • Eloquent Health & Wellness
    Tyger Valley, 0084, South Africa
  • Acinadem Altunizade
    Istanbul, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Mar 2024, 51 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 51 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Dec 4, 2019
StartActual
Dec 20, 2019
Primary completionActual
Mar 31, 2024
CompletionActual
Apr 1, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04185558
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Dec 20, 2019
Primary completion
Mar 31, 2024
Completion
Apr 1, 2024
Last update
May 14, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion